Company intelligence / Profile preview
CHOSA Oncology
Lund, Swedenchosaoncology.com ↗
- Ownership
- Public · CHOSA
- Development stage
- Phase 2
01
Overview
CHOSA Oncology has shown promising results in Phase 2 trials for LiPlaCis in metastatic breast cancer, with patients scoring high in the DRP reading (DRP 80+) showing 2.5 times longer median progression-free survival. The company has also completed a Phase 2b trial for Onilcamotide in prostate cancer.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule drugSynthetic peptide vaccineTherapeutic vaccineLiposomal formulation
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaboration with Professor Solange Peters and Professor Rolf Stahel for analyzing biopsies from the lung cancer SPLENDOUR Trial
Beyond the preview
Go deeper on CHOSA Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHOSA Oncology.